Germany · Delayed Price · Currency is EUR Implantica AG Company Description
Implantica AG engages in the research and distribution of medical implants in Switzerland.
The company’s lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease.
It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system to support its pipeline of smart medical implants designed for a safe and secure control and monitoring over the internet; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite.
In addition, the company develops UriControl, a hand pumped artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform.
Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for monitoring the expansion of the aneurysms.
The company was founded in 2015 and is based in Vaduz, Liechtenstein.
| Country | Liechtenstein |
| Founded | 2015 |
| Industry | Surgical and Medical Instruments and Apparatus |
| Employees | 50 |
| CEO | Peter Forsell |
Contact Details
Address: Aeulestrasse 45 Vaduz, 9490 Liechtenstein | |
| Website | implantica.com |
Stock Details
| Ticker Symbol | 8IM1 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Peter Forsell | Chief Executive Officer |
| Andreas Öhrnberg | Chief Financial Officer |